Boston Scientific discloses $642,000 in quarterly lobbying spend
Alpha Vantage · Quiver Quantitative · · AI-summarised by FinFlash
Boston Scientific Corporation disclosed $642,000 in lobbying expenditures for Q3 2026, spanning medical device regulation, patient access, tax provisions and supply chain resiliency. Filings cite work on the National Defense Authorization Act, breakthrough product access legislation and ethylene oxide emissions rules. Analyst consensus shows 25 buy ratings and a $59.55 target versus a $43.00 price, implying 38.5% upside.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.